Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure

Next Previous
Trial Profile

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ampreloxetine (Primary)
  • Indications Orthostatic hypotension
  • Focus Registrational; Therapeutic Use
  • Acronyms REDWOOD
  • Sponsors Theravance Biopharma

Most Recent Events

  • 20 Nov 2025 According to a Theravance Biopharma media release, company will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. the event will also provide an overview of the ongoing CYPRESS study of ampreloxetine, and the strategic design choices of the study, informed by the positive results observed in patients with MSA in the REDWOOD study.
  • 29 Oct 2025 According to a Theravance Biopharma media release, data from this trial will presented at the 36th International Symposium on the Autonomic Nervous System, organized by the American Autonomic Society (AAS), taking place November 5-8, 2025, in Clearwater Beach, FL.
  • 07 Apr 2025 According to a Theravance Biopharma media release, results form these studies supported registrational study in patients with nOH and MSA, CYPRESS currently ongoing.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top